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Background
Millions of patients with allergy to birch pollen develop
clinically cross-reactive IgE against Bet v 1-like proteins in
plant foods. Specific immunotherapy (SIT) with birch pol-
len extracts induces the biosynthesis of Bet v 1-specific
immunoglobulin (Ig)G4. IgG4 is believed to act as a block-
ing antibody preventing IgE binding to Bet v 1, thus
alleviating allergic symptoms. Only little information on
the location and relationship of IgE and IgG4 binding sites
of Bet v 1 is available. In this study we seek to identify
epitopes of IgE and IgG4 antibodies on Bet v 1.
Methods
A competitive immunoscreening of phage-displayed
peptides was applied to predict Bet v 1 epitopes of aller-
gen-specific IgE and IgG4 antibodies by bioinformatic
means. Predicted epitope residues potentially critical for
antibody binding were substituted by site-directed muta-
genesis. Recombinant Bet v 1 (rBet v 1) and rBet v 1
variants were purified from Escherichia coli. The pro-
teins were physicochemically characterized using circu-
lar dichroism (CD) and dynamic light scattering. To test
the IgE and IgG4 interactions with rBet v 1 variants,
western blot analyses, ELISA, and cellular mediator
release assays were performed.
Results
Several rBet v 1 variants were expressed in E. coli. Cir-
cular dichroism and structural modeling of the variants
revealed Bet v 1-like theoretical secondary structure
topology. The rBet v 1 variants showed reduced IgE and
IgG4 binding with sera of birch pollen allergic subjects
in western blot analyses and competitive ELISAs. The
rBet v 1 variants showed decreased IgE-mediated media-
tor release in humanized rat basophil leukemia cells sen-
sitized with sera of birch pollen allergic subjects.
Conclusion
We identified critical residues in IgE and IgG4epitopes
of Bet v 1. Although patient-specific variability was
observed, the antibody interactions of the respective
rBet v 1 variants were compromised for both IgE and
IgG4, respectively. We conclude that epitopes for IgE
and IgG4 share common residues critical for antibody
interaction, suggesting an overlap of IgE and IgG4-bind-
ing sites on the molecular surface of Bet v 1. The
knowledge of clinically relevant immunoglobulin-aller-
gen interactions on the molecular level enables new
strategies in the diagnosis, prognosis, and therapy of
both birch pollen allergies and birch pollen-related food
allergies.
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